FDA Authorizes Additional Batch of the J&J COVID-19 Vaccine
An additional batch of the Janssen COVID-19 vaccine has been authorized by FDA under the Emergency Use Authorization.
FDA authorized an additional batch of Janssen’s COVID-19 vaccine manufactured at Emergent BioSolutions’ facility in Baltimore under Emergency Use Authorization (EUA), the agency announced on July 2, 2021.
Thus far, four batches have been authorized to be manufactured at the Emergent BioSolutions plant in the Janssen EUA, though the facility isn’t officially an authorized manufacturing facility. FDA reviewed facility records, including quality testing, and concluded the batches were suitable for use.
FDA said it will continue to work through issues that arise at the Emergent facility with Janssen and Emergent BioSolutions management.
Previously, FDA authorized the use of two batches of Janssen’s vaccine under EUA on June 11, 2021.
Source: FDA
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.
